Methods for treating cutaneous lupus erythematosus and systemic lupus erythematosus

JP2024501430A5Inactive Publication Date: 2024-12-09BIOGEN MA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023533928
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-03
Filing Date
2021-12-03
Publication Date
2024-12-09
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a significant unmet need for targeted and effective treatments for cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE), as current therapies are limited and have a high impact on quality of life.

Method used

The use of anti-BDCA2 antibodies, administered subcutaneously every 4 weeks at a dose of 225 mg, with optional loading doses, to target and modulate the activity of blood dendritic cell antigen 2 (BDCA2) in patients with CLE or SLE, optionally combined with antimalarial drugs or corticosteroids.

Benefits of technology

The anti-BDCA2 antibody treatment effectively reduces disease activity in CLE and SLE by decreasing Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI-A) scores and Systemic Lupus Erythematosus Response Index (SRI-4) scores, providing clinically meaningful improvements in disease severity and quality of life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Dosage regimens of anti-blood dendritic cell antigen 2 antibodies for use in treating cutaneous lupus erythematosus and systemic lupus erythematosus are provided. The disclosure relates, in part, to dosing regimens of anti-BDCA2 antibodies for use in treating CLE and SLE. In a first aspect, the disclosure features a method of treating CLE or SLE in a human subject in need thereof. The method includes administering to the human subject an anti-BDCA2 antibody subcutaneously at a dose of 225 mg every four weeks.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Application No. 63 / 121,194, filed December 3, 2020, the contents of which are incorporated herein by reference in their entirety.

[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The ASCII copy, created on November 12, 2021, is named 13751-0337WO1_SL.txt and is 17,573 bytes in size.

[0003] This application relates to the clinical use of anti-blood dendritic cell antigen 2 antibodies in the treatment of cutaneous and systemic lupus erythematosus. [Background technology]

[0004] Blood dendritic cell antigen 2 (BDCA2) is a C-type lectin expressed on human plasmacytoid dendritic cells (pDCs) (Dzionek et al., J. Immunol., 165:6037-6046 (2000)), a specialized population of bone marrow-derived cells that secrete type I interferons (IFNs) in response to Toll-like receptor (TLR) ligands. BDCA2 consists of a single extracellular carbohydrate recognition domain (CRD) belonging to the type II C-type lectin group at its C-terminus, a transmembrane region, and a short cytoplasmic tail without signaling motifs at its N-terminus. BDCA2 transmits intracellular signals through the associated transmembrane adaptor FcεRIγ to induce a B cell receptor (BCR)-like signaling cascade.

[0005] Cutaneous lupus erythematosus (CLE) is an autoimmune disease that affects the skin and can present with or without systemic symptoms.

[0006] Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease affecting multiple organ systems with unpredictable disease severity and periods of illness or exacerbations alternating with periods of remission. Given the lack of specific treatments for CLE and SLE and the significant impact of the disease on quality of life, there remains a significant unmet need for the development of new targeted and effective therapeutics. [Prior art documents] [Non-patent literature]

[0007] [Non-Patent Document 1] Dzionek et al., J. Immunol., 165:6037-6046(2000) Summary of the Invention

[0008] This disclosure relates, in part, to dosing regimens of anti-BDCA2 antibodies for use in treating CLE and SLE.

[0009] In a first aspect, the disclosure features a method of treating CLE or SLE in a human subject in need thereof. The method includes administering to the human subject an anti-BDCA2 antibody at a dose of 225 mg subcutaneously every four weeks. The anti-BDCA2 antibody includes an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), each of which includes the following complementarity determining regions (CDRs) of VH: VH-CDR1, VH-CDR2, and VH-CDR3, where VH-CDR1 consists of the amino acid sequence set forth in SEQ ID NO:1, VH-CDR2 consists of the amino acid sequence set forth in SEQ ID NO:2, and VH-CDR3 consists of the amino acid sequence set forth in SEQ ID NO:3. VH-CDR1, VH-CDR2, and VH-CDR3, and VL CDRs VL-CDR1, VL-CDR2, and VL-CDR3, each consisting of the amino acid sequence set forth in SEQ ID NO: 4, VL-CDR2, and VL-CDR3, each consisting of the amino acid sequence set forth in SEQ ID NO: 5, and VL-CDR1, VL-CDR2, and VL-CDR3, each consisting of the amino acid sequence set forth in SEQ ID NO: 6. Optionally, the human subject is administered a loading dose of the anti-BDCA2 antibody two weeks after the first administration of the anti-BDCA2 antibody. Optionally, the loading dose is 225 mg. Optionally, the loading dose is 450 mg. The patient population may be adult or pediatric CLE or adult or pediatric SLE.

[0010] The present disclosure also features a method of treating lupus nephritis, neuropsychiatric lupus (NPSLE), Sjogren's syndrome, systemic sclerosis (scleroderma), morphea, psoriasis, rheumatoid arthritis, inflammatory bowel disease (IBD), dermatomyositis, polymyositis, type I diabetes, or cytokine release syndrome in a human subject in need of such treatment. The patient population for any of these indications may be adult or pediatric. The method includes administering anti-BDCA2 antibody subcutaneously to the human subject at a dose of 225 mg every 4 weeks. The anti-BDCA2 antibody comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), each of which comprises the following: VH complementarity determining regions (CDRs), VH-CDR1, VH-CDR2, and VH-CDR3, in which VH-CDR1 has the amino acid sequence set forth in SEQ ID NO: 1, VH-CDR2 has the amino acid sequence set forth in SEQ ID NO: 2, and VH-CDR3 has the amino acid sequence set forth in SEQ ID NO: 3. VH-CDR1, VH-CDR2, and VH-CDR3, and VL CDRs VL-CDR1, VL-CDR2, and VL-CDR3, each consisting of the amino acid sequence set forth in SEQ ID NO: 4, VL-CDR2, and VL-CDR3, each consisting of the amino acid sequence set forth in SEQ ID NO: 5, and VL-CDR1, VL-CDR2, and VL-CDR3, each consisting of the amino acid sequence set forth in SEQ ID NO: 6. Optionally, the human subject is administered a loading dose of the anti-BDCA2 antibody two weeks after the first administration of the anti-BDCA2 antibody. Optionally, the loading dose is 225 mg. Optionally, the loading dose is 450 mg.

[0011] In certain examples, the human subject is administered a second loading dose of the anti-BDCA2 antibody 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 weeks (e.g., 18 weeks) after the first administration of the anti-BDCA2 antibody. In some cases, the second loading dose is 225 mg. In some cases, the second loading dose is 450 mg.

[0012] In some cases, the anti-BDCA2 antibody is administered at a dose of 225 mg every 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 days (e.g., every 4 weeks) for at least 16 weeks. In some cases, the anti-BDCA2 antibody is administered at a dose of 225 mg once a month for at least 16 weeks. In some cases, the anti-BDCA2 antibody is administered at a dose of 225 mg every 4 weeks for at least 52 weeks. In some cases, the anti-BDCA2 antibody is administered at a dose of 225 mg every 4 weeks indefinitely. In some cases, the anti-BDCA2 antibody is administered at a dose of 225 mg every 4 weeks until a medical professional determines that it is no longer necessary. In some cases, the anti-BDCA2 antibody is administered at a dose of 225 mg every 4 weeks for the patient's lifetime (i.e., chronic use).

[0013] In certain instances, at least 4 (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, etc.) doses of the anti-BDCA2 antibody are administered to the human subject. In some instances, at least 12 doses of the anti-BDCA2 antibody are administered to the human subject. In other instances, at least 13 doses of the anti-BDCA2 antibody are administered to the human subject. In certain instances, at least 14 doses of the anti-BDCA2 antibody are administered to the human subject. In some cases, at least 15 doses of the anti-BDCA2 antibody are administered to the human subject. In other cases, at least 16 doses of the anti-BDCA2 antibody are administered to the human subject. In other cases, the dose of the anti-BDCA2 antibody is administered to the human subject until a medical professional determines that it is no longer necessary. In other cases, at least 16 doses of the anti-BDCA2 antibody are administered to the human subject. In other cases, the dose of the anti-BDCA2 antibody is administered to the human subject for the patient's lifetime (i.e., chronic use).

[0014] In some cases, the CLE disease is mild CLE activity. In some cases, the CLE disease is moderate CLE activity. In other examples, the CLE disease is severe CLE activity. In some cases, the type of CLE is acute CLE (ACLE). In some cases, the type of CLE is subacute CLE (SCLE). In some cases, the type of CLE is chronic CLE (CCLE). In some cases, the CLE is discoid lupus erythematosus (DLE). In some cases, the CLE is active CLE. In some cases, the CLE is active CLE and the human subject is intolerant and / or ineffective to antimalarial and topical steroid therapy. In some cases, the active CLE is CLE with systemic symptoms of lupus and the human subject is intolerant and / or ineffective to antimalarial and topical steroid therapy. In some cases, the active CLE is CLE without systemic symptoms of lupus, and the human subject is intolerant or ineffective against antimalarial and / or topical steroid therapy. In certain examples, the human subject achieves a clinically meaningful reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index A (CLASI-A) score from baseline, for example, a 4-point reduction, about 16 weeks to about 24 weeks after the first administration of the anti-BDCA2 antibody. In some cases, the human subject achieves a clinically meaningful reduction in disease activity from baseline, for example, a score of 0, 1, 2, or 3, on a CLE-specific Investigator Global Assessment (IGA) (CLA-IGA-R), about 16 weeks to about 24 weeks after the first administration of the anti-BDCA2 antibody.

[0015] In certain examples, the SLE is active SLE. Optionally, the human subject has active autoantibody-positive SLE. In certain cases, the human subject has active autoantibody-positive SLE, and the human subject is receiving non-biological standard treatment for SLE. Optionally, the SLE is moderate SLE. In certain cases, the SLE is severe SLE. Optionally, the SLE is active SLE with active joint and / or skin symptoms. Optionally, the human subject has a SLEDAI-2K≧6 at the start of treatment, excluding alopecia, lupus-associated headache, and organic brain disease. In certain cases, the human subject has a clinical SLEDAI-2K≧4 at the start of treatment, excluding alopecia, lupus-associated headache, and organic brain disease, anti-dsDNA, low complement C3 and / or C4, or fever. In certain cases, the human subject has BILAG-2004 grade A in one or more organ systems, or BILAG-2004 grade B in two or more organ systems at the start of treatment. In certain examples, the human subject achieves an SRI-4 response at about 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, or 52 weeks after initiation of treatment with the anti-BDCA2 antibody. In certain examples, the human subject achieves a Joint-50 response rate at about 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24, or 52 weeks after initiation of treatment with the anti-BDCA2 antibody in human subjects with at least four swollen and tender joints at the start of treatment.

[0016] In some cases, the anti-BDCA2 antibody is formulated as a sterile liquid pharmaceutical composition comprising the anti-BDCA2 antibody at a concentration of 150 mg / ml, sucrose at a concentration of 3%, L-histidine at a concentration of 20 mM, L-arginine HCl at a concentration of 100 mM, glutathione (GSH or a combination of GSH and GSSG) at a concentration of 0.4 mM, and polysorbate 80 (PS80) at a concentration of 0.05%, and the pharmaceutical composition has a pH of 5.7.

[0017] In some cases, the VH comprises or consists of a sequence at least 80% identical to the amino acid sequence of SEQ ID NO: 7, and the VL comprises or consists of a sequence at least 80% identical to the amino acid sequence of SEQ ID NO: 8. In certain examples, the VH comprises or consists of a sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 7, and the VL comprises or consists of a sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 8. In other examples, the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 7, and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 8.

[0018] In some cases, an anti-BDCA2 antibody used in the methods described herein comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), each of which comprises: VH complementarity determining regions (CDRs), VH-CDR1, VH-CDR2, and VH-CDR3, wherein VH-CDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 1, VH-CDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 2, and VH-CDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 3. R3, and VL CDRs VL-CDR1, VL-CDR2, and VL-CDR3, wherein VL-CDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 4, VL-CDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 5, and VL-CDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 6, wherein the VH comprises or consists of a sequence at least 80% identical to the amino acid sequence of SEQ ID NO: 7, and the VL comprises or consists of a sequence at least 80% identical to the amino acid sequence of SEQ ID NO: 8.

[0019] In some cases, an anti-BDCA2 antibody used in the methods described herein comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), each of which comprises: VH complementarity determining regions (CDRs), VH-CDR1, VH-CDR2, and VH-CDR3, wherein VH-CDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 1, VH-CDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 2, and VH-CDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 3. R3, and VL CDRs VL-CDR1, VL-CDR2, and VL-CDR3, wherein VL-CDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 4, VL-CDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 5, and VL-CDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 6, wherein the VH comprises or consists of a sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 7, and the VL comprises or consists of a sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 8.

[0020] In some cases, an anti-BDCA2 antibody used in the methods described herein comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), each of which comprises: VH complementarity determining regions (CDRs), VH-CDR1, VH-CDR2, and VH-CDR3, wherein VH-CDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 1, VH-CDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 2, and VH-CDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 3. R3, and VL CDRs VL-CDR1, VL-CDR2, and VL-CDR3, wherein VL-CDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 4, VL-CDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 5, and VL-CDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 6, wherein the VH comprises or consists of a sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 7, and the VL comprises or consists of a sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 8.

[0021] In some cases, an anti-BDCA2 antibody used in the methods described herein comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), each of which comprises: VH complementarity determining regions (CDRs), VH-CDR1, VH-CDR2, and VH-CDR3, wherein VH-CDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 1, VH-CDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 2, and VH-CDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 3. R3, and VL CDRs VL-CDR1, VL-CDR2, and VL-CDR3, wherein VL-CDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 4, VL-CDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 5, and VL-CDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 6, wherein the VH comprises or consists of a sequence at least 97% identical to the amino acid sequence of SEQ ID NO: 7, and the VL comprises or consists of a sequence at least 97% identical to the amino acid sequence of SEQ ID NO: 8.

[0022] In some cases, an anti-BDCA2 antibody used in the methods described herein comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), each of which comprises: VH complementarity determining regions (CDRs), VH-CDR1, VH-CDR2, and VH-CDR3, wherein VH-CDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 1, VH-CDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 2, and VH-CDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 3. R3, and VL CDRs VL-CDR1, VL-CDR2, and VL-CDR3, wherein VL-CDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 4, VL-CDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 5, and VL-CDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 6, wherein the VH comprises or consists of a sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 7, and the VL comprises or consists of a sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 8.

[0023] In some cases, the anti-BDCA2 antibody used in the methods described herein is an antibody described in US Pat. No. 9,902,775, which is incorporated herein by reference.

[0024] In certain instances, the anti-BDCA2 antibody comprises an immunoglobulin heavy chain and an immunoglobulin light chain. In some instances, the heavy chain comprises or consists of a sequence at least 80% identical to the amino acid sequence of SEQ ID NO:9, and the light chain comprises or consists of a sequence at least 80% identical to the amino acid sequence of SEQ ID NO:10. In other instances, the heavy chain comprises or consists of a sequence at least 90% identical to the amino acid sequence of SEQ ID NO:9, and the light chain comprises or consists of a sequence at least 90% identical to the amino acid sequence of SEQ ID NO:10. In some instances, the heavy chain comprises or consists of the amino acid sequence set forth in SEQ ID NO:9, and the light chain comprises or consists of the amino acid sequence set forth in SEQ ID NO:10.

[0025] In some cases, the method further comprises administering to the human subject at least one of an antimalarial drug, a corticosteroid, an immunosuppressant, or an anti-B-lymphocyte stimulator (BLyS) monoclonal antibody. In certain examples, the method further comprises administering to the human subject at least one of mycophenolic acid, azathioprine, methotrexate, a calcineurin inhibitor, or cyclophosphamide.

[0026] In another aspect, the disclosure features a pre-filled syringe containing a sterile preparation of an anti-BDCA2 antibody. The pre-filled syringe is suitable for subcutaneous administration of the anti-BDCA2 antibody at a fixed dose of 225 mg. The anti-BDCA2 antibody comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), each of which has a complementarity determining region (CDR) of VH, VH-CDR1, VH-CDR2, and VH-CDR3, in which VH-CDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 1, VH-CDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 2, and VH-CDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 3. and VL-CDR1, VL-CDR2, and VL-CDR3, which are CDRs of VL-CDR1, VL-CDR2, and VL-CDR3, respectively, and VL-CDR1, VL-CDR2, and VL-CDR3, which include or consist of the amino acid sequence set forth in SEQ ID NO:4, VL-CDR2 includes or consists of the amino acid sequence set forth in SEQ ID NO:5, and VL-CDR3 includes or consists of the amino acid sequence set forth in SEQ ID NO:6.

[0027] The pre-filled syringes described herein may be fitted with device components such as finger flanges and safety needle shields to facilitate administration, and may also be fitted to autoinjectors to facilitate self-administration by the patient and / or administration by a caregiver.

[0028] In some cases, the VH comprises or consists of a sequence at least 80% identical to the amino acid sequence of SEQ ID NO: 7, and the VL comprises or consists of a sequence at least 80% identical to the amino acid sequence of SEQ ID NO: 8. In certain examples, the VH comprises or consists of a sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 7, and the VL comprises or consists of a sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 8. In other examples, the VH comprises or consists of the amino acid sequence set forth in SEQ ID NO: 7, and the VL comprises or consists of the amino acid sequence set forth in SEQ ID NO: 8.

[0029] In other examples, the anti-BDCA2 antibody comprises an immunoglobulin heavy chain and an immunoglobulin light chain. In some cases, the heavy chain comprises or consists of a sequence at least 80% identical to the amino acid sequence of SEQ ID NO:9, and the light chain comprises or consists of a sequence at least 80% identical to the amino acid sequence of SEQ ID NO:10. In other cases, the heavy chain comprises or consists of a sequence at least 90% identical to the amino acid sequence of SEQ ID NO:9, and the light chain comprises or consists of a sequence at least 90% identical to the amino acid sequence of SEQ ID NO:10. In some cases, the heavy chain comprises or consists of the amino acid sequence set forth in SEQ ID NO:9, and the light chain comprises or consists of the amino acid sequence set forth in SEQ ID NO:10.

[0030] In some cases, the anti-BDCA2 antibody is formulated as a sterile liquid pharmaceutical composition comprising the anti-BDCA2 antibody at a concentration of 150 mg / ml, sucrose at a concentration of 3%, L-histidine at a concentration of 20 mM, L-arginine HCl at a concentration of 100 mM, glutathione (GSH or a combination of GSH and GSSG) at a concentration of 0.4 mM, and polysorbate 80 (PS80) at a concentration of 0.05%, and the pharmaceutical composition has a pH of 5.7.

[0031] Optionally, the syringe is a United States Pharmacopoeia or European Pharmacopoeia Type 1 clear glass syringe stoppered with a rubber stopper.

[0032] In some cases, the syringe is a Type I glass 2.25 mL pre-filled syringe with a butyl rubber plunger (ethylene tetrafluoroethylene coated).

[0033] For the avoidance of doubt, it is emphasized that expressions such as "in some embodiments", "in one particular embodiment", "in one particular example", "optionally", "in a further embodiment", "in one embodiment" and "in a further embodiment" are used and that any of the embodiments described therein should be read with the combination of each of the features of those embodiments in mind, and that the present disclosure should treat the combination of features of those embodiments in the same way as those detailed in one embodiment. The same is the case for any combination of embodiments and features shown in the appended claims and examples, which are also intended to be combined with the features of the corresponding embodiments disclosed herein, and only for the sake of consistency and conciseness, the embodiments are characterized by a dependency relationship, but in fact each embodiment and combination of features that may be interpreted by a (multiple) dependency relationship should be considered as literally disclosed and not as a selection among different alternatives. In this regard, it will be understood by those skilled in the art that the embodiments and features disclosed in the examples are intended to be generalized to equivalents having the same functions as those exemplified therein.

[0034] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. In the practice or testing of the present invention, methods and materials similar or equivalent to those described herein can be used, but exemplary methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present application, including definitions, will take precedence. The materials, methods, and examples are merely illustrative and are not intended to be limiting.

[0035] Other features and advantages of the invention will become apparent from the following detailed description, and from the claims. [Brief description of the drawings]

[0036] [Figure 1] Pharmacokinetic time course of BIIB059 across dosing in a Phase 2 study. Median concentrations (dots) observed at each BIIB059 dose of 50 mg (bottom curve), 150 mg (middle curve), and 450 mg (top curve) with corresponding 90% prediction intervals (shaded areas) in participants with CLE in a Phase 2 study (n=500). Bold lines are predicted median values. Target engagement levels of BDCA2 (0.64 μg / mL), IC90 levels of IFN-α (9.7 μg / mL), and 3xIC90 levels are shown. [Diagram 2] Forest plot of CLASI-A scores: Percent change from baseline at week 16, showing Mixed Model for Repeated Measures subgroup analyses. [Diagram 3] A-B provide exposure-response analysis from the Phase 2 study. A shows observed versus simulated values ​​for the exposure-response model using the CLASI-A week 16 trough concentrations in the Phase 2 study. The observed change from baseline in CLASI-A and associated standard deviations were determined according to four bins of observed BIIB059 trough concentrations (plus placebo, i.e., readings at dose 0) and plotted with the median exposure within each bin. The solid line is the median simulated exposure-response trend response (1,000 replicates). The shaded areas indicate the associated 90% CI. B is a box plot showing the range (median, interquartile, and 5 / 95 percentile) of observed trough concentrations. EC90 is the target engagement of BDAC2 at 0.64 μg / mL. IFN90 is the inhibition level at 9.7 μg / mL. [Figure 4]Graph showing percentage of participants with BIIB059 levels equal to or greater than the CLASI-A EC90 (10.1 μg / mL) at week 16. Simulation based on 1,000 Phase 3 trials assuming BIIB059 doses of 50 mg to 450 mg Q4W with a loading dose in week 2 (loading dose equal to the loading dose), and an ADA incidence of 19%. Dashed line represents 80% of participants. [Diagram 5] Pharmacokinetic time course of BIIB059 at doses of 150 mg and 225 mg. Simulated BIIB059 PK time course (n=1,000) following Q4W dosing of 150 mg (left) and 225 mg (right) in patients with CLE. PK time points observed at the 150 mg dose in a Phase 2 study are indicated by filled circles (ADA positive) and circles (ADA negative). 80% prediction intervals are indicated in the shaded areas with medians indicated by solid black lines. Dashed blue line indicates estimated CLASI-A EC90 (10.1 μg / mL) and IFNα IC90 (9.7 μg / mL) shown in black. For 225 mg (right), an ADA incidence of 19% was assumed. [Figure 6A] FIG. 1 is a schematic diagram of the Phase 3 CLE study design. [Figure 6B] FIG. 1 is another schematic diagram of the CLE study design. [Figure 7] 2 is a graph of the pharmacokinetic time course of BIIB059 across doses in participants with SLE. Median concentrations (dots) observed at each BIIB059 dose of 50 mg (lower trace), 150 mg (middle trace), and 450 mg (upper trace) versus the corresponding 90% prediction interval (n=500) in participants with SLE. The bold lines are the predicted median values ​​for 50 mg, 150 mg, and 450 mg, respectively. The target engagement level of BDCA2 (0.64 μg / mL) is indicated by the dashed line at the bottom. The other dashed line indicates the IC90 level of INF-α (9.7 μg / mL), and the bold black line from the top represents the 3xIC90 level. The bold line at the top represents the mean BIIB059 concentration from the highest IV dose of 20 mg / kg that was deemed safe and well tolerated in Phase 1. [Figure 8]Visual predictive check plot of the exposure-response SRI-4 model for BIIB059 Cavg in participants with SLE. SRI-4 response = ≥4 decrease in Systemic Lupus Erythematosus Response Index. [Figure 9] Depiction of the percentage of simulated Phase 3 trials achieving mean differences in SRI-4 response compared to placebo of ≥0.17, ≥0.2, ≥0.23, and ≥0.25 based on the exposure-response model for SRI-4 at week 52. SRI-4 response = reduction of ≥4 in the Systemic Lupus Erythematosus Response Index. [Figure 10] Figure 1. Predicted pharmacokinetic time course in participants with SLE after SC dosing at 225 mg and 450 mg Q4W in Phase 3. Simulated pharmacokinetic time course of BIIB059 after SC dosing at 225 mg and 450 mg Q4W in patients with SLE (n=500). 80% prediction intervals are shown in the lower (225 mg) and upper (450 mg) shaded regions, with the median value in black. The upper dashed black line shows the estimated CLASI-A EC90 (10.1 μg / mL) and the IFNα IC90 (9.7 μg / mL) is shown in the lower dashed line. The upper solid line represents the mean BIIB059 concentration from the highest IV dose of 20 mg / kg that was deemed safe and well tolerated in Phase 1. An ADA incidence of 19% was assumed. [Figure 11A] FIG. 1 is a schematic diagram of the Phase 3 SLE trial design. [Figure 11B] FIG. 1 is another schematic diagram of the SLE study design. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0037] The present application provides dosing regimens for anti-BDCA2 antibodies for use in treating CLE or SLE.

[0038] BDCA2 BDCA2 is a type II C-type lectin that is specifically expressed in plasmacytoid dendritic cells (pDCs). BDCA2 consists of a single extracellular carbohydrate recognition domain (CRD) at its C-terminus, a transmembrane region, and a short cytoplasmic tail with no signaling motifs at its N-terminus. BDCA2 transmits intracellular signals through the associated transmembrane adaptor FcεRIγ. Antibody-mediated ligation of BDCA2 recruits spleen tyrosine kinase (SYK) to phosphorylated immunoreceptor tyrosine-based activation motifs (ITAMs) of FcεRIγ. Activation of Syk leads to activation of B-cell linker (Blnk), Bruton's tyrosine kinase (BTK), and phospholipase Cγ2 (PLCγ2), which upregulates Ca2 + This leads to mobilization of

[0039] The amino acid sequence of the human BDCA2 protein (Genbank® Accession No. NP_569708.1) is shown below (the transmembrane domain is in italics, the ectodomain is underlined): [ka]

[0040] The amino acid sequence of human FcεRIγ (Genbank® Accession No. NP_004097.1) is shown below. 1 MIPAVVLLLL LLVEQAAALG EPQLCYILDA ILFLYGIVLT LLYCRLKIQV 51 RKAAITSYEK SDGVYTGLST RNQETYETLK HEKPPQ* (SEQ ID NO: 30)

[0041] Anti-BDCA2 antibody In some embodiments, the anti-BDCA2 antibody or BDCA2-binding fragment thereof used in the compositions and methods described herein comprises the complementarity determining regions (CDRs) of the three heavy chain variable domains of the antibody designated "BIIB059". In some embodiments, the anti-BDCA2 antibody or BDCA2-binding fragment thereof comprises the CDRs of the three light chain variable domains of BIIB059. In yet other embodiments, the anti-BDCA2 antibody or BDCA2-binding fragment thereof comprises the CDRs of the three heavy chain variable domains and the CDRs of the three light chain variable domains of BIIB059. The CDRs can be based on any CDR definition in the art, for example, Kabat, Chothia, Chothia of Abysis, modified Chothia / AbM definition, or can be based on the contact definition. The CDR sequences of BIIB059 according to these exemplary CDR definitions are shown in Table A below. [Table A]

[0042] In some embodiments, the anti-BDCA2 antibody or BDCA2-binding fragment thereof comprises a VH CDR1 that comprises or consists of the amino acid sequence set forth in SEQ ID NO: 1 or 17, a VH CDR2 that comprises or consists of the amino acid sequence set forth in SEQ ID NO: 2, and a VH CDR3 that comprises or consists of the amino acid sequence set forth in SEQ ID NO: 3. In some embodiments, the anti-BDCA2 antibody or BDCA2-binding fragment thereof comprises a VL CDR1 that comprises or consists of the amino acid sequence set forth in SEQ ID NO: 4, a VL CDR2 that comprises or consists of the amino acid sequence set forth in SEQ ID NO: 5, and a VL CDR3 that comprises or consists of the amino acid sequence set forth in SEQ ID NO: 6.

[0043] In certain embodiments, the anti-BDCA2 antibody or BDCA2-binding fragment thereof comprises a CDR that comprises or consists of the amino acid sequence set forth in SEQ ID NOs: 1-6. In other embodiments, the anti-BDCA2 antibody or BDCA2-binding fragment thereof comprises a CDR that comprises or consists of the amino acid sequence set forth in SEQ ID NOs: 11-16. In yet other embodiments, the anti-BDCA2 antibody or BDCA2-binding fragment thereof comprises a CDR that comprises or consists of the amino acid sequence set forth in SEQ ID NOs: 17-22. In yet another embodiment, the anti-BDCA2 antibody or BDCA2-binding fragment thereof comprises a CDR that comprises or consists of the amino acid sequence set forth in SEQ ID NOs: 23-28. In one embodiment, the anti-BDCA2 antibody or BDCA2-binding fragment thereof comprises a VH CDR1 comprising or consisting of the amino acid sequence set forth in SEQ ID NO:1 or 17, a VH CDR2 comprising or consisting of the amino acid sequence set forth in SEQ ID NO:2, and a VH CDR3 comprising or consisting of the amino acid sequence set forth in SEQ ID NO:3, as well as a VL CDR1 comprising or consisting of the amino acid sequence set forth in SEQ ID NO:4, a VL CDR2 comprising or consisting of the amino acid sequence set forth in SEQ ID NO:5, and a VL CDR3 comprising or consisting of the amino acid sequence set forth in SEQ ID NO:6.

[0044] BIIB059 is an exemplary anti-BDCA2 antibody that can be used in the compositions and methods described herein. BIIB059 is a humanized antibody with two glycosylated human IgG1 heavy chains and two human kappa light chains that specifically binds to BDCA2 on the surface of plasmacytoid dendritic cells. The wild-type IgG1 sequence contains a single N-linked glycosylation site and binds to Fc receptors with an affinity typical of this class of molecules. BIIB059 is described in U.S. Patent No. 9,902,775.

[0045] The variable heavy chain (VH) of BIIB059 comprises or consists of the following amino acid sequence: [ka]

[0046] The variable light chain (VL) of BIIB059 comprises or consists of the following amino acid sequence: [ka]

[0047] In certain embodiments, the anti-BDCA2 antibody or BDCA2-binding fragment thereof comprises a VH having the amino acid sequence set forth in SEQ ID NO: 7. In some embodiments, the anti-BDCA2 antibody or antigen-binding fragment thereof selectively binds to the ectodomain of human BDCA2 and comprises a VH domain that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of the VH domain of BIIB059 (SEQ ID NO: 7), or that differs from SEQ ID NO: 7 by at least 1-5 amino acid residues, but less than 40, 30, 20, 15, or 10 residues. In certain examples, these antibodies (i) bind to human or cynomolgus monkey BDCA2 but do not significantly bind to BDCA2 of phylogenetic species below primates, and / or (ii) inhibit TLR7 / TLR9-induced production of type I interferons and other cytokines or chemokines by human pDCs, and / or (iii) mediate internalization of BDCA2 from the surface of pDCs, and / or (iv) downregulate CD32a and / or CD62L from the surface of pDCs, and / or (v) deplete pDCs in vitro by ADCC or CDC.

[0048] In certain embodiments, the anti-BDCA2 antibody or BDCA2-binding fragment thereof comprises a VL having the amino acid sequence set forth in SEQ ID NO: 8. In some embodiments, the anti-BDCA2 antibody or antigen-binding fragment thereof selectively binds to the ectodomain of human BDCA2 and comprises a VL domain that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of the VL domain of BIIB059 (SEQ ID NO: 8), or that differs from SEQ ID NO: 8 by at least 1-5 amino acid residues, but less than 40, 30, 20, 15, or 10 residues. In certain examples, these antibodies (i) bind to human or cynomolgus monkey BDCA2 but do not significantly bind to BDCA2 of phylogenetic species below primates, and / or (ii) inhibit TLR7 / TLR9-induced production of type I interferons and other cytokines or chemokines by human pDCs, and / or (iii) mediate internalization of BDCA2 from the surface of pDCs, and / or (iv) downregulate CD32a and / or CD62L from the surface of pDCs, and / or (v) deplete pDCs in vitro by ADCC or CDC.

[0049] In some embodiments, the anti-BDCA2 antibody or BDCA2-binding fragment thereof comprises a VH having the amino acid sequence set forth in SEQ ID NO:7 and a VL having the amino acid sequence set forth in SEQ ID NO:8. In some embodiments, the anti-BDCA2 antibody or antigen-binding fragment thereof selectively binds to the ectodomain of human BDCA2 and comprises (i) a VH domain that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of the VH domain of BIIB059 (SEQ ID NO:7), and (ii) a VL domain that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of the VL domain of BIIB059 (SEQ ID NO:8), or differs from SEQ ID NO:7 and / or SEQ ID NO:8 by at least 1-5 amino acid residues but less than 40, 30, 20, 15, or 10 residues. In certain examples, these antibodies (i) bind to human or cynomolgus monkey BDCA2 but do not significantly bind to BDCA2 of phylogenetic species below primates, and / or (ii) inhibit TLR7 / TLR9-induced production of type I interferons and other cytokines or chemokines by human pDCs, and / or (iii) mediate internalization of BDCA2 from the surface of pDCs, and / or (iv) downregulate CD32a and / or CD62L from the surface of pDCs, and / or (v) deplete pDCs in vitro by ADCC or CDC.

[0050] The antibody consisting of the mature heavy chain (SEQ ID NO: 9) and mature light chain (SEQ ID NO: 10) listed below is referred to as "BIIB059" as used herein. [ka]

[0051] In the above VH, VL, HC, and LC sequences, CDR1, 2, and 3 based on the Kabat definition are underlined and bolded. The italicized and bolded sequences in the VH and HC are the additional N-terminal sequences found in CDR1 based on the modified Chothia / AbM definition.

[0052] In certain embodiments, the anti-BDCA2 antibody or BDCA2-binding fragment thereof comprises a HC having the amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the anti-BDCA2 antibody or antigen-binding fragment thereof selectively binds to the ectodomain of human BDCA2 and comprises a HC that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO: 9, or comprises a HC that differs from SEQ ID NO: 9 by at least 1-5 amino acid residues but less than 40, 30, 20, 15, or 10 residues.

[0053] In certain embodiments, the anti-BDCA2 antibody or BDCA2-binding fragment thereof comprises an LC having the amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the anti-BDCA2 antibody or antigen-binding fragment thereof selectively binds to the ectodomain of human BDCA2 and comprises an LC that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO: 10, or differs from SEQ ID NO: 10 by at least 1-5 amino acid residues but less than 40, 30, 20, 15, or 10 residues.

[0054] In some embodiments, the anti-BDCA2 antibody or BDCA2-binding fragment thereof comprises a HC having the amino acid sequence set forth in SEQ ID NO:9 and a LC having the amino acid sequence set forth in SEQ ID NO:10. In some embodiments, the anti-BDCA2 antibody or antigen-binding fragment thereof selectively binds to the ectodomain of human BDCA2 and comprises (i) an HC that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO:9, and (ii) an LC that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO:10, or differs from SEQ ID NO:9 and / or SEQ ID NO:10 by at least 1-5 amino acid residues but less than 40, 30, 20, 15, or 10 residues.

[0055] In certain embodiments, the anti-BDCA2 antibody is an IgG antibody. In certain embodiments, the anti-BDCA2 antibody has a heavy chain constant region selected from, for example, IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE. In one embodiment, the anti-BDCA2 antibody is of the IgG1 isotype. In another embodiment, the anti-BDCA2 antibody is of the IgG2 isotype. In yet another embodiment, the anti-BDCA2 antibody is of the IgG3 isotype. In further embodiments, the antibody has a light chain constant region selected from, for example, a human kappa or human lambda light chain. In some embodiments, the anti-BDCA2 antibody is an IgG1 / kappa antibody. In certain embodiments, the anti-BDCA2 antibody has an EC of 7-15 μg / mL. 50 In certain embodiments, the antibody comprises a human Fc region that binds to FcγRIIa (CD32a) with an EC 50 In certain embodiments, the antibody comprises a human Fc region that binds to FcγRIIa (CD32a) with an EC 50In certain embodiments, the antibody comprises a human Fc region that binds to FcγRIIa (CD32a) with an EC 50 The anti-BDCA2 antibody comprises a human Fc region that binds to FcγRIIa (CD32a) at 100-300 ng / mL. In some cases, the heavy chain constant region is human, or a modified version of a human constant region. In certain examples, the human constant region may comprise at least one and up to 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 substitutions. In certain embodiments, the modified human Fc region is a modified human IgG1 Fc region. In some cases, the constant region of the anti-BDCA2 antibody may be modified by mutation of one or more amino acid residues to impart a desired functional property (e.g., altered effector function or half-life, reduced glycosylation). For example, the N-linked glycosylation site may be substituted to prevent or reduce N-linked glycosylation of the Fc region (e.g., human IgG1 Fc region).

[0056] In some embodiments, the anti-BDCA2 antibody is a full-length (complete) antibody or substantially full-length. The protein may include at least one, preferably two, complete heavy chains, and at least one, preferably two, complete light chains. In some embodiments, the anti-BDCA2 antibody is a BDCA2-binding fragment. In some cases, the BDCA2-binding fragment is a Fab, Fab', F(ab')2, Facb, Fv, single-chain Fv (scFv), sc(Fv)2, or diabody.

[0057] Antibodies, such as BIIB059, or BDCA2-binding fragments thereof, can be made, for example, by preparing and expressing a synthetic gene encoding the recited amino acid sequence, or by mutating a human germline gene to obtain a gene encoding the recited amino acid sequence. Additionally, this and other anti-BDCA2 antibodies can be produced, for example, using one or more of the following methods.

[0058] Anti-BDCA2 antibody composition The present disclosure also provides compositions (e.g., pharmaceutical compositions) comprising the anti-BDCA2 antibodies described herein. For example, the anti-BDCA2 antibody compositions include an anti-BDCA2 antibody comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein the VH comprises the VH-CDR of BIIB059, and the VL comprises the VL-CDR. In certain examples, the VH-CDR comprises or consists of the amino acid sequences set forth in SEQ ID NO:1 or 17, SEQ ID NO:2, and SEQ ID NO:3, and the VL-CDR comprises or consists of the amino acid sequences set forth in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6. In some embodiments, an anti-BDCA2 antibody composition comprises an anti-BDCA2 antibody comprising (i) a VH comprising or consisting of an amino acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:7, and (ii) a VL comprising or consisting of an amino acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:8. In certain embodiments, the anti-BDCA2 antibody composition comprises an anti-BDCA2 antibody comprising (i) a heavy chain comprising or consisting of an amino acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 9, and (ii) a light chain comprising or consisting of an amino acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 10. The pharmaceutical composition may further comprise any pharma- ceutically acceptable carrier and / or excipient.

[0059] In some cases, the pharmaceutical composition comprises the anti-BDCA2 antibody at a concentration of 150 mg / ml, sucrose at a concentration of 3%, L-histidine at a concentration of 20 mM, L-arginine HCl at a concentration of 100 mM, glutathione (GSH or a combination of GSH and GSSG) at a concentration of 0.4 mM, and polysorbate 80 (PS80) at a concentration of 0.05%. In some cases, the pharmaceutical composition has a pH of 5.5 to 6.0. In one example, the pharmaceutical composition has a pH of 5.7.

[0060] In some cases, the pharmaceutical composition comprises the anti-BDCA2 antibody at a concentration of 100-200 mg / ml, sucrose at a concentration of 1-4%, L-histidine at a concentration of 10-30 mM, L-arginine HCl at a concentration of 75-150 mM, glutathione (GSH or a combination of GSH and GSSG) at a concentration of 0.2-0.6 mM, and polysorbate 80 (PS80) at a concentration of 0.02%-0.08%. In some cases, the pharmaceutical composition has a pH of 5.5-6.0. In one example, the pharmaceutical composition has a pH of 5.7.

[0061] In some cases, the pharmaceutical composition is a pharmaceutical composition described in US20190284281, which is incorporated herein by reference.

[0062] In some cases, the compositions described herein may be formulated or administered with at least one of an antimalarial drug, a corticosteroid, an immunosuppressant, or an anti-B-lymphocyte stimulator (BLyS) monoclonal antibody. In certain examples, the compositions of the present disclosure may be formulated or administered with at least one of mycophenolic acid, azathioprine, methotrexate, a calcineurin inhibitor, or cyclophosphamide. In one example, the compositions described herein are administered with an antimalarial drug. In another example, the compositions described herein are administered with a corticosteroid.

[0063] The antibody or the pharmaceutical composition can be provided in a pre-filled syringe or pump.The pharmaceutical composition comprises the sterile preparation of anti-BDCA2 antibody described herein.The pre-filled syringe or pump can be adapted to subcutaneously administer the anti-BDCA2 antibody at a fixed dose of 225mg.

[0064] The composition of the present disclosure can be packaged as a kit with information on how the antibody is used to treat CLE or SLE. The kit can include at least one of an antimalarial drug, a corticosteroid, an immunosuppressant, or an anti-B-lymphocyte stimulator (BLyS) monoclonal antibody. In a particular example, the kit can include at least one of mycophenolic acid, azathioprine, methotrexate, a calcineurin inhibitor, or cyclophosphamide. In one example, the kit includes an antimalarial drug. In another example, the kit includes a corticosteroid.

[0065] Treatment method The anti-BDCA2 antibodies described herein, or pharmaceutical compositions comprising the anti-BDCA2 antibodies described herein, may be used to treat or prevent various immunological disorders, such as inflammatory and autoimmune disorders (e.g., CLE, SLE, lupus nephritis, neuropsychiatric lupus (NPSLE), Sjogren's syndrome, systemic sclerosis (scleroderma), morphea, psoriasis, rheumatoid arthritis, inflammatory bowel disease (IBD), dermatomyositis, polymyositis, type I diabetes, or cytokine release syndrome). In vitro data indicates that anti-BDCA2 antibodies can neutralize and / or inhibit inflammatory cytokines and chemokines produced by pDCs, downregulate CD32a, inhibit immune complex stimulation of pDCs, and / or cause downregulation or shedding of CD62L. The anti-BDCA2 antibodies of the present disclosure, or BDCA2-binding fragments thereof, may be combined with antimalarial drugs (e.g., HCQ) to improve potential therapeutic efficacy in the treatment of inflammatory and autoimmune disorders. Anti-BDCA2 antibodies may be used to reduce levels of cytokines and chemokines, such as type I interferons, type III interferons, IL-6, TNF-α, MIP1-α and MIP1-β, CCL5, and IP-10. Type I IFNs constitute a multi-member family of cytokines that includes 13 IFN-α subtypes, IFN-β, -ε, -κ, -ω, -δ, and -τ. (Theofilopoulos, Annu. Rev. Immunol., 23:307-36 (2005)). Type III interferons consist of three IFN-λ molecules, termed IFN-λ1, IFN-λ2, and IFN-λ3 (also called IL29, IL28A, and IL28B, respectively). The anti-BDCA2 antibodies described herein provide a more powerful therapeutic approach than treatments that attempt to reduce specific IFN subtypes with neutralizing antibodies by depleting and / or attenuating pDC function. Moreover, the pDC-specific therapeutic approach with the anti-BDCA2 antibody is more selective and potentially safer than a global blockade of the IFN response. For example, the anti-BDCA2 antibody described herein effectively eliminates type I IFN from pDCs while preserving other sources of IFN that may be required in the case of viral infection.

[0066] In one example, the anti-BDCA2 antibody described herein or a pharmaceutical composition comprising the anti-BDCA2 antibody described herein is used for the treatment of CLE in a human subject in need of such treatment. Optionally, the CLE disease is mild CLE activity. Optionally, the CLE disease is moderate CLE activity. In another example, the CLE disease is severe CLE activity. Optionally, the CLE disease is acute CLE (ACLE). Optionally, the CLE disease is subacute CLE (SCLE). Optionally, the CLE disease is chronic CLE (CCLE). In certain cases, the CLE disease is discoid lupus erythematosus (DLE). Optionally, the CLE disease is active CLE. Optionally, the CLE disease is active CLE and the human subject is intolerant and / or ineffective to antimalarial and topical steroid therapy. In certain cases, the active CLE disease is CLE with systemic symptoms of lupus, and the human subject is intolerant or refractory to antimalarial and / or topical steroid therapy. In some cases, the active CLE disease is CLE without systemic symptoms of lupus, and the human subject is intolerant or refractory to antimalarial and / or topical steroid therapy. In certain examples, the human subject achieves a clinically meaningful reduction, e.g., a 4-point reduction, in Cutaneous Lupus Erythematosus Disease Area and Severity Index A (CLASI-A) score from baseline about 16 weeks to about 24 weeks after the first administration of the anti-BDCA2 antibody.See Albrecht et al., “The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus” J Invest Dermatol. 2005;125(5):889-94, Bonilla-Martinez et al., “The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus” Arch Dermatol. 2008;144(2):173-80, Klein et al., “Using the CLASI to assess disease severity and responsiveness to therapy in cutaneous lupus erythematosus” Arthritis Rheumatism. 2009;60:903, Klein et al., “Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus” Arch Dermatol. 2011;147(2):203-8, and Chakka et al., “Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus” J Am Acad Dermatol. 2021 Jun;84(6):1562-1567.In some cases, the human subject achieves a clinically meaningful reduction in disease activity from baseline, e.g., a score of 0, 1, 2, or 3, on a CLE-specific IGA about 16 weeks to about 24 weeks after the initial administration of the anti-BDCA2 antibody.

[0067] In another example, the anti-BDCA2 antibody described herein or the pharmaceutical composition comprising the anti-BDCA2 antibody described herein is used for the treatment of SLE in a human subject in need of such treatment. In a particular example, the SLE is active SLE. Optionally, the human subject has active autoantibody-positive SLE. In a particular case, the human subject has active autoantibody-positive SLE, and the human subject is receiving standard treatment for SLE. Optionally, the SLE is moderate SLE. Optionally, the SLE is severe SLE. Optionally, the SLE is active SLE with active joint and / or skin symptoms. Optionally, the human subject has SLEDAI-2K≧6 at the start of treatment, excluding alopecia, lupus-related headache, and organic brain disease. In certain cases, the human subject has a clinical SLEDAI-2K≧4 at the start of treatment, excluding alopecia, lupus-related headache and organic brain disease, anti-dsDNA, low complement C3 and / or C4, or fever. In certain cases, the human subject has BILAG-2004 grade A in one or more organ systems, or BILAG-2004 grade B in two or more organ systems at the start of treatment. In certain examples, the human subject achieves an SRI-4 response at about 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, or 52 weeks after the start of treatment with the anti-BDCA2 antibody. In certain examples, the human subject achieves a Joint-50 response rate about 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24, or 52 weeks after initiation of treatment with the anti-BDCA2 antibody in a human subject with at least four swollen and tender joints at the start of treatment. In certain examples, the human subject has a CLASI-A score of ≧10 at baseline and achieves a CLASI-50 response about 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, or 52 weeks after initiation of treatment with the anti-BDCA2 antibody.

[0068] In some cases, the anti-BDCA2 antibody is administered to the human subject at a dose of 225 mg every 4 weeks by subcutaneous injection.In some cases, the subject is administered at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, at least 11 times, at least 12 times, or 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 times.In some cases, the subject is administered until a medical professional determines that it is no longer necessary.In some cases, the subject is administered for the lifetime of the subject.In some cases, the subject is administered a loading dose of the anti-BDCA2 antibody about 2 weeks after the first administration of the anti-BDCA2 antibody. In some cases, the subject is administered a loading dose of the anti-BDCA2 antibody about 2 weeks, 3 weeks, 4 weeks, or 5 weeks after the first administration of the anti-BDCA2 antibody.In some cases, the loading dose is 225 mg.In some cases, the subject is administered a second loading dose of the anti-BDCA2 antibody 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24, 25, or 26 weeks (e.g., 18 weeks) after the first administration of the anti-BDCA2 antibody.In some cases, the second loading dose is 225 mg.

[0069] In some cases, the method of treating the human subject is by administering a pharmaceutical composition of an anti-BDCA2 antibody. The pharmaceutical composition includes the anti-BDCA2 antibody at a concentration of 150 mg / ml, sucrose at a concentration of 3%, L-histidine at a concentration of 20 mM, L-arginine HCl at a concentration of 100 mM, glutathione (GSH or a combination of GSH and GSSG) at a concentration of 0.4 mM, and polysorbate 80 (PS80) at a concentration of 0.05%. In some cases, the pharmaceutical composition has a pH of 5.5 to 6.0. In one example, the pharmaceutical composition has a pH of 5.7. The pharmaceutical composition is administered subcutaneously to the human subject every 4 weeks to provide a dose of 225 mg of the anti-BDCA2 antibody.

[0070] In some embodiments, in all of the above methods of treatment, the anti-BDCA2 antibody selectively binds to the ectodomain of human BDCA2 and comprises (i) a VH domain that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of the VH domain of BIIB059 (SEQ ID NO:7), and / or (ii) a VL domain that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of the VL domain of BIIB059 (SEQ ID NO:8), or differs from SEQ ID NO:7 and / or SEQ ID NO:8 by at least 1-5 amino acid residues, but less than 40, 30, 20, 15, or 10 residues. In certain examples, these anti-BDCA2 antibodies (i) bind to human or cynomolgus monkey BDCA2 but do not significantly bind to BDCA2 of phylogenetic species below primates, and / or (ii) inhibit TLR7 / TLR9-induced production of type I interferons and other cytokines or chemokines by human pDCs, and / or (iii) mediate internalization of BDCA2 from the surface of pDCs, and / or (iv) downregulate CD32a and / or CD62L from the surface of pDCs, and / or (v) deplete pDCs in vitro by ADCC or CDC.

[0071] In certain embodiments, in all of the above therapeutic methods, the anti-BDCA2 antibody selectively binds to the ectodomain of human BDCA2 and comprises (i) a HC that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO:9, and / or (ii) a LC that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO:10, or differs from SEQ ID NO:9 and / or SEQ ID NO:10 by at least 1-5 amino acid residues, but less than 40, 30, 20, 15, or 10 residues.

[0072] Below are examples of the practice of the present invention, which are not to be construed as limiting the scope of the invention in any manner. EXAMPLES

[0073] Example 1: Pharmacokinetic time course study using BIIB059 A phase 2 study of CLE tested fixed doses of 50, 150, and 450 mg of BIIB059 administered subcutaneously (SC) every 4 weeks (Q4W). A loading dose was administered in week 2 (for patients receiving 50 mg SC Q4W, the loading dose was also 50 mg; for patients receiving 150 mg SC Q4W, the loading dose was also 150 mg; for patients receiving 450 mg SC Q4W, the loading dose was also 450 mg). As shown in Figure 1, these three doses of BIIB059 demonstrated different exposures with minimal overlap. The observed PK was consistent with the PK / PD model predictions, indicating that the doses tested in this study were within the expected efficacy range of BIIB059. All doses were considered safe and well tolerated.

[0074] The primary endpoint at week 16, defined as the percent change from baseline in CLASI-A score, was met (Table 1), demonstrating a dose-response. [Table 1]

[0075] Statistical significance was achieved at the 150 mg and 450 mg doses. Efficacy of BIIB059 was also demonstrated across subgroups, particularly at the 150 mg and 450 mg doses, with the 50 mg dose showing more inconsistent clinical results (Figure 2). Overall, the Phase 2 data indicate that doses of BIIB059 ≥150 mg are required to achieve clinically meaningful improvements in CLE skin disease activity across multiple thresholds and subgroups.

[0076] The relationship between serum exposure to BIIB059 and its efficacy (assessed by CLASI-A) in participants with CLE was characterized using data from a Phase 2 study. The effect of BIIB059 on the percent change from baseline in CLASI-A at week 16 was described using the Emax function. The predicted trough concentrations from the model were used as input data for the exposure-response analysis. The point estimate of the BIIB059 concentration associated with 90% of maximal effect (EC90) on CLASI-A (10.1ug / mL) was comparable to the IC90 of IFN-α (9.7ug / mL). Figure 3 shows the observed (±SD) and predicted (90%CI) change from baseline in CLASI-A at week 16 as a function of BIIB059 trough concentration in participants with CLE (primary endpoint). The proportion of participants achieving a CLASI-50 response increased with increasing BIIB059 exposure, with maximal efficacy estimated to be achieved at an exposure equivalent to 150 mg SC Q4W dosing (approximately the IFN-α IC90).

[0077] Of note, efficacy was reduced at the 50 mg dose, suggesting that beyond BDAC2 internalization, modulation of downstream IFN-α levels is required to maximize the therapeutic effect of BIIB059 in participants with CLE.

[0078] Example 2: Dose Selection for Phase 3 Trials of CLE Exposure-response modeling was used to simulate a Q4W SC regimen of BIIB059. Based on the exposure level of participants achieving a CLASI-A EC90 or greater, the dose of 225 mg Q4W SC will be selected for the Phase 3 study.

[0079] Figure 4 is a model simulation showing the percent of participants with BIIB059 levels above 10.1ug / mL (or CLASI-A EC90). Figure 5 is a model simulation showing the PK over time following dosing of 150mg and 225mg BIIB059. The model simulation suggests that a higher percentage of participants would exceed the EC90 at the 225mg dose compared to the 150mg dose at week 16. At the 50mg dose, less than 5% of subjects had trough levels of BIIB059 above the EC90, resulting in reduced efficacy at week 16 (Figure 3). According to the exposure-response analysis of the Phase 2 study, the 225mg dose Q4W SC is expected to maximize the likelihood of efficacy of BIIB059 in participants with CLE. Exposure levels at trough concentrations for this proposed Phase 3 dose are expected to keep at least 80% of participants above the CLASI-A EC90.

[0080] The impact of immunogenicity was also evaluated on BIIB059 exposure in relation to dose selection in phase 3. In participants with CLE in the phase 2 study, 5 (19.2%), 4 (16.0%), and 5 (10.4%) were assessed as positive for anti-BIIB059 antibodies in the 50, 150, and 450 mg BIIB059 dose groups, respectively. All placebo participants were negative for anti-BIIB059 antibodies. As shown in Figure 5, participants who were ADA positive at the 150 mg dose in phase 2 (filled dots in Figure 5) had exposure levels that were consistently above the EC90 during the dosing phase. In phase 3, assuming an ADA incidence of 19%, BIIB059 exposure is expected to remain above efficacy levels in at least 80% of participants who received the 225 mg dose (shaded area in the right panel of Figure 5). This indicates that the impact of immunogenicity on exposure is not expected to translate into clinically meaningful differences in efficacy or safety.

[0081] In summary, BIIB059 225 mg Q4W SC is an appropriate dose for CLE based on safety, PK, PD (BDCA2 internalization), efficacy and estimated potency in inhibiting pDC IFN-α production (concentration resulting in 90% inhibition of response [IC90]).

[0082] Example 3: Phase 3 CLE Study Design The study is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 study (Figure 6A). Approximately 384 participants from 160 sites worldwide will be enrolled and randomly assigned in a 2:1 ratio in each study to receive either BIIB059 225 mg SC Q4W or matching placebo, respectively, during a 24-week double-blind, placebo-controlled (DBPC) treatment period. Participants who complete the DBPC treatment period will then be passed on to a 28-week blinded extension (BE) treatment period, during which all participants will receive BIIB059 225 mg SC Q4W while remaining blinded to their initial treatment assignment.

[0083] Study participants have active CLE with or without systemic symptoms and are ineffective and / or intolerant to antimalarial drugs. The diagnosis of CLE has been histologically confirmed in the past or at screening. Disease activity is defined by CLASI-A. All participants must have active skin symptoms defined as follows: a total CLASI-A score ≥ 10 and a CLA-IGA-R score ≥ 3, as determined at screening and confirmed at randomization, and at least one SCLE lesion with a minimal CLASI-A erythema score ≥ 2 and a CLASI-A scaling score ≥ 1, and / or at least one active CCLE lesion with a minimal CLASI-A erythema score ≥ 2 and a CLASI-D scarring score ≥ 1, a CLA-IGA-R erythema score ≥ 3, and a score of ≥ 1 for any of the four morphological features (scaling, edema, follicular involvement, or secondary changes) in the CLA-IGA-R solidarity. Participants with active SCLE and / or CCLE lesions plus active ACLE, with or without SLE, will be permitted to participate in the study. Additionally, participants must have documentation of current failure to respond to antimalarial treatment used for ≥12 weeks at screening, or have previously discontinued antimalarial medication due to poor tolerability and / or side effects and / or lack of therapeutic benefit after 12 weeks of use. Other standard lupus treatments, such as but not limited to oral corticosteroids, mycophenolate, or azathioprine, are permitted within the specifications outlined in the protocol and should have been initiated at least 12 weeks prior to randomization. Treatment received at randomization must remain constant for the duration of the study.

[0084] The objective of this Phase 3 study is to determine the efficacy and safety of BIIB059 in participants with active CLE who are intolerant to or refractory to antimalarial treatment, with or without systemic symptoms.

[0085] The study will incorporate regionally defined primary and key secondary endpoints: one set of endpoints will be defined for the United States and another set for the rest of the world (ROW).

[0086] The primary objective is to demonstrate efficacy of BIIB059 in reducing disease activity in CLE, as assessed by response rates of CLA-IGA-R score of 0 or 1, defined as clear or almost clear skin disease activity, in BIIB059-treated versus placebo-treated participants at week 16 in the US, and by CLASI-70 responder rates in BIIB059-treated versus placebo-treated participants at week 24 in the ROW, defined as at least a 70% reduction in CLASI-A score from baseline (Table 2). [Table 2-1] [Table 2-2]

[0087] Key secondary objectives (Table 2) will evaluate the efficacy of BIIB059 225 mg Q4W SC compared to placebo in reducing skin disease activity as measured by CLA-IGA-R score 0-1, CLA-IGA-R erythema features or solidarity for four morphologic features, and CLASI-70 response rate at week 16 in the US and week 24 in the ROW in participants.

[0088] Key secondary endpoints supporting the secondary objectives are shown in Table 2.

[0089] Eligible participants who complete 52 weeks of treatment with investigational drug will be offered to participate in a long-term extension study (LTE). Participants who discontinue study participation or study drug prematurely, as well as participants who complete the blinded extension period but choose not to participate in the LTE, will complete a 24-week safety follow-up.

[0090] The LTE study is a multicenter, open-label, interventional trial that will enroll approximately 400-500 participants from the parent Phase 3 study. The LTE study is planned to further evaluate the safety and efficacy profile of BIIB059 with at least two additional years of follow-up. The eligible population includes all participants who complete and consent to continue in two 52-week Phase 3 studies. The primary objective of this LTE study is to evaluate the long-term safety (total exposure and frequency of adverse events [AEs]) of BIIB059. The proposed dose of 225 mg Q4W SC of BIIB059 in this LTE study is identical to that planned for use in the Phase 3 study of BIIB059.

[0091] Another schematic diagram of the CLE study design is shown in Figure 6B.

[0092] Example 4: Dose Selection for Phase 3 Trials in SLE A Phase 2 study in SLE tested fixed doses of 50, 150, and 450 mg of BIIB059 administered subcutaneously (SC) every 4 weeks (Q4W). As shown in Figure 7, these 50, 150, and 450 mg doses in SLE demonstrated different exposures with minimal overlap. The observed PK was consistent with the PK / PD model predictions, indicating that the doses tested in Phase 2 in SLE were within the therapeutic range of BIIB059. All doses were considered safe and well tolerated.

[0093] An exposure-response (ER) analysis was performed to characterize the relationship between BIIB059 exposure and efficacy as measured through the SLE Responder Index-4 (SRI-4). The ER model was then used to perform clinical trial simulations to aid in the selection of a phase 3 dosing regimen in participants with active SLE.

[0094] This SRI-4 model was developed using data from a study that included mostly active patients (48%) who received placebo (43%) and BIIB059 450 mg. The remaining 9% of this data was evenly distributed between the lower doses of 50 mg and 150 mg. The ER model for the probability of SRI4 was a logistic regression model that included a piecewise linear function of the time course of power and the BIIB059 Cavg (fixed at 55 μg / mL based on sensitivity analysis). Figure 8 shows the predicted proportion of patients with SRI4 (95% CI) against the BIIB059 Cavg, overlaid on the simulated dataset (dotted line) and the observed data (solid line).

[0095] A clinical trial simulation was performed using the final ER model of SRI4 response to inform dose selection in SLE participants in Phase 3. Higher doses of BIIB059 provided a higher probability of success in achieving a significant treatment difference in SRI4 response compared to placebo (Figure 9).

[0096] This Phase 3 study proposes BIIB059 doses of 225 mg (low dose) and 450 mg (high dose) SC Q4W with an additional dose at week 2. In previous clinical trials, exposures associated with doses ranging from 50 mg to 450 mg Q4W (additional dose at week 2) were considered well tolerated among participants with SLE and / or CLE. Exposure levels at trough concentrations of the 225 mg dose were associated with IC of IFN-α associated with efficacy of BIIB059 in Phase 2. 90 are expected to consistently exceed 19% (Figure 10), explaining the immunogenicity rates of up to 19% observed in Phase 2, which are not expected to impact efficacy.

[0097] Example 5: Phase 3 SLE Study Design This Phase 3 study is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of BIIB059 in participants with active SLE (Figure 11A). Approximately 540 participants (180 / arm / study) will be enrolled worldwide and randomized in a 1:1:1 ratio to receive BIIB059 450 mg or BIIB059 225 mg Q4W SC or matching placebo, respectively, for a 52-week DBPC treatment period, followed by a 24-week SFU period (no treatment). Participants who complete this Phase 3 study will be eligible to participate in a separate long-term extension (LTE) study.

[0098] All participants will have a diagnosis of SLE and moderate to severe disease activity. All participants will be treated with stable non-biologic standard of care (SoC) for lupus, must have started treatment ≥12 weeks prior to study enrollment, and must have been on a stable dose for at least 4 weeks prior to randomization. For participants receiving a dose >10 mg / day at baseline, mandatory corticosteroid taper will be required to begin 4 weeks after the first dose to achieve a corticosteroid target dose of 7.5 mg / day. One corticosteroid rescue will be permitted between weeks 5 and 12.

[0099] These study populations included participants with active SLE who were being treated with lupus SoCs. 1. At the time of informed consent, participants must be 16 years of age or older, where permitted by local institutional regulations. 2. Participants must have been diagnosed with SLE at least 24 weeks prior to screening by a physician who meets diagnostic requirements and meet the 2019 EULAR / ACR SLE classification criteria. 3. Participant has a modified SLEDAI-2K (excluding alopecia, lupus-related headache, and organic brain syndrome) ≥ 6 at screening (centrally reviewed) and randomization according to the following: If 4 of the required SLEDAI-2K entry points are for arthritis, then at least 4 joints that are both swollen and tender (at least 4 occurring in the PIP, MCP, or wrist joints) based on a 28 joint count assessment must also be included. If 2 of the required SLEDAI-2K entry points are for rash, then the rash must be due to cutaneous manifestations of ACLE, SCLE, and / or CCLE (e.g., DLE). 4. Participants will have a modified clinical SLEDAI-2K score of ≥4 at screening (centrally reviewed) and at random assignment (excluding anti-dsDNA, low complement C3 and / or C4 levels, alopecia, fever, lupus-related headache, and organic brain syndrome). 5. Participant has BILAG-2004 grade A in 1 or more organ systems or BILAG-2004 grade B in 2 or more organ systems at screening (central review) and at randomization. Participants must have been treated with one of the following fixed lupus SOC therapies for at least 12 weeks prior to screening and had been receiving stable doses for at least 4 weeks prior to randomization: a. Combination treatment with antimalarials and corticosteroids and / or immunosuppressants b. Antimalarial monotherapy c. Treatment with oral corticosteroids (OCS) and / or immunosuppressants. 6. Participant has one of the following by a central laboratory at screening: A. ANA by immunofluorescence assay ≥ 1:80 b. Higher than normal levels of anti-dsDNA antibodies C. higher than normal levels of anti-Smith antibodies

[0100] The primary and key secondary objectives and endpoints of this study are shown in Table 3. [Table 3-1] [Table 3-2]

[0101] Another schematic diagram of the SLE study design is shown in FIG. 11B.

[0102] Other embodiments Although the present invention has been described in conjunction with its detailed description, the foregoing description is intended to be illustrative, not limiting, of the scope of the invention as defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims

1. 1. A composition for the treatment of cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) in a human subject in need thereof, the composition comprising an anti-BDCA2 antibody, the anti-BDCA2 antibody being administered subcutaneously to the human subject at a dose of 225 mg every 4 weeks, the anti-BDCA2 antibody comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), the VH and VL each comprising: (a) VH complementarity determining regions (CDRs), VH-CDR1, VH-CDR2, and VH-CDR3; VH-CDR1 consists of the amino acid sequence set forth in SEQ ID NO:1, VH-CDR2 consists of the amino acid sequence set forth in SEQ ID NO:2; The VH-CDR1, VH-CDR2, and VH-CDR3 consist of the amino acid sequence set forth in SEQ ID NO: 3; and (b) the VL CDRs VL-CDR1, VL-CDR2, and VL-CDR3, VL-CDR1 consists of the amino acid sequence set forth in SEQ ID NO:4, VL-CDR2 consists of the amino acid sequence set forth in SEQ ID NO:5, The VL-CDR1, VL-CDR2, and VL-CDR3 consist of the amino acid sequence set forth in SEQ ID NO:

6.

2. 2. The composition of claim 1, wherein the human subject is administered a loading dose of the anti-BDCA2 antibody two weeks after a first administration of the anti-BDCA2 antibody.

3. 1. A composition for the treatment of cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) in a human subject in need thereof, the composition comprising an anti-BDCA2 antibody, the anti-BDCA2 antibody being administered subcutaneously to the human subject at a dose of 225 mg every four weeks, the human subject being administered a loading dose of 225 mg of the anti-BDCA2 antibody two weeks after a first administration of the anti-BDCA2 antibody, the anti-BDCA2 antibody comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), the VH and VL each comprising: (a) VH complementarity determining regions (CDRs), VH-CDR1, VH-CDR2, and VH-CDR3; VH-CDR1 consists of the amino acid sequence set forth in SEQ ID NO:1, VH-CDR2 consists of the amino acid sequence set forth in SEQ ID NO:2; The VH-CDR1, VH-CDR2, and VH-CDR3 consist of the amino acid sequence set forth in SEQ ID NO: 3; and (b) the VL CDRs VL-CDR1, VL-CDR2, and VL-CDR3, VL-CDR1 consists of the amino acid sequence set forth in SEQ ID NO:4, VL-CDR2 consists of the amino acid sequence set forth in SEQ ID NO:5, The VL-CDR1, VL-CDR2, and VL-CDR3 consist of the amino acid sequence set forth in SEQ ID NO:

6.

4. The composition of any one of claims 1 to 3, wherein the human subject is administered a second loading dose of the anti-BDCA2 antibody.

5. 5. The composition of claim 4, wherein the second loading dose is 225 mg.

6. The composition of any one of claims 1 to 3, wherein the anti-BDCA2 antibody is administered at a dose of 225 mg every 4 weeks for at least 16 weeks.

7. The composition of any one of claims 1 to 6, wherein the anti-BDCA2 antibody is administered at a dose of 225 mg every 4 weeks for at least 52 weeks.

8. The composition of any one of claims 1 to 5, wherein at least four administrations of the anti-BDCA2 antibody are administered to the human subject.

9. The composition of any one of claims 1 to 5, wherein at least 12 administrations of the anti-BDCA2 antibody are administered to the human subject.

10. The composition of any one of claims 1 to 5, wherein at least 14 administrations of the anti-BDCA2 antibody are administered to the human subject.

11. The composition of any one of claims 1 to 5, wherein at least 16 administrations of the anti-BDCA2 antibody are administered to the human subject.

12. The composition according to any one of claims 1 to 11, wherein the CLE disease is moderate CLE.

13. The composition according to any one of claims 1 to 11, wherein the CLE disease is severe CLE.

14. The composition according to any one of claims 1 to 11, wherein the type of CLE is acute CLE (ACLE).

15. The composition according to any one of claims 1 to 11, wherein the type of CLE is subacute CLE (SCLE).

16. The composition according to any one of claims 1 to 11, wherein the type of CLE is chronic CLE (CCLE).

17. The composition of claim 16, wherein the CCLE is discoid lupus erythematosus (DLE).

18. The composition of any one of claims 1 to 11, wherein the CLE disease is active CLE.

19. 19. The composition of claim 18, wherein the active CLE is associated with systemic symptoms of lupus and the human subject is intolerant to or refractory to antimalarial therapy.

20. 19. The composition of claim 18, wherein the active CLE is not associated with systemic symptoms of lupus and the human subject is intolerant or refractory to antimalarial therapy.

21. 21. The composition of any one of claims 1-20, wherein the human subject achieves a clinically meaningful reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index A (CLASI-A) score from baseline about 16 weeks to about 24 weeks after a first administration of the anti-BDCA2 antibody.

22. 21. The composition of any one of claims 1-20, wherein the human subject achieves a clinically meaningful reduction in disease activity from baseline in a CLE-specific CLA-IGA-R about 16 weeks to about 24 weeks after the first administration of the anti-BDCA2 antibody.

23. The composition of any one of claims 1 to 11, wherein the SLE disease is active SLE.

24. The composition of any one of claims 1 to 11, wherein the human subject has active autoantibody-positive SLE.

25. The composition of any one of claims 1 to 11, wherein the human subject has active autoantibody-positive SLE, and the human subject is receiving standard treatment for SLE.

26. The composition of any one of claims 1 to 11, wherein the SLE disease is moderate SLE.

27. The composition according to any one of claims 1 to 11, wherein the SLE disease is severe SLE.

28. 12. The composition of any one of claims 1 to 11, wherein the human subject has a modified SLEDAI-2K > 6 at the start of treatment, excluding alopecia, fever, lupus-associated headache, and organic brain syndrome.

29. 12. The composition of any one of claims 1 to 11, wherein the human subject has a clinical SLEDAI-2K > 4, excluding alopecia, lupus-associated headache and organic brain disease, anti-dsDNA, low complement C3 and / or C4 levels, or fever, at the start of treatment.

30. 12. The composition of any one of claims 1-11, wherein the human subject has BILAG-2004 grade A in one or more organ systems or BILAG-2004 grade B in two or more organ systems at the start of treatment.

31. The composition of any one of claims 1 to 11, wherein the human subject is treated with an antimalarial drug, an oral corticosteroid, and / or an immunosuppressant prior to initiation of treatment with the anti-BDCA2 antibody.

32. The anti-BDCA2 antibody, the anti-BDCA2 antibody at a concentration of 150 mg / ml; sucrose at a concentration of 3%, L-histidine at a concentration of 20 mM, L-Arginine HCl at a concentration of 100 mM, Glutathione at a concentration of 0.4 mM, and Polysorbate 80 (PS80) at a concentration of 0.05% 32. The composition of any one of claims 1 to 31, formulated as a sterile liquid pharmaceutical composition comprising:

33. A composition according to any one of claims 1 to 32, (i) the VH comprises a sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 7, and the VL comprises a sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 8; or (ii) the VH comprises a sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:7 and the VL comprises a sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:8; or (iii) the VH comprises the amino acid sequence set forth in SEQ ID NO:7 and the VL comprises the amino acid sequence set forth in SEQ ID NO:

8.

34. 34. The composition of any one of claims 1 to 33, wherein the anti-BDCA2 antibody comprises an immunoglobulin heavy chain and an immunoglobulin light chain, (i) the heavy chain comprises a sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO:9 and the light chain comprises a sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO:10; or (ii) the heavy chain comprises a sequence at least 90% identical to the amino acid sequence of SEQ ID NO:9 and the light chain comprises a sequence at least 90% identical to the amino acid sequence of SEQ ID NO:10; or (iii) the composition, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 9 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:

10.

35. 1. A pre-filled syringe comprising a sterile preparation of an anti-BDCA2 antibody, the pre-filled syringe being suitable for subcutaneous administration of the anti-BDCA2 antibody at a fixed dose of 225 mg, the anti-BDCA2 antibody comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), the VH and VL each comprising: (a) VH complementarity determining regions (CDRs), VH-CDR1, VH-CDR2, and VH-CDR3; VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:1, VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:2, The VH-CDR1, VH-CDR2, and VH-CDR3 comprise the amino acid sequence set forth in SEQ ID NO:3; and (b) the VL CDRs VL-CDR1, VL-CDR2, and VL-CDR3, VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:4, VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:5, The VL-CDR1, VL-CDR2, and VL-CDR3, wherein VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:

6.

36. 36. The pre-filled syringe of claim 35, (i) the VH comprises a sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 7, and the VL comprises a sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 8; or (ii) the VH comprises a sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 7, and the VL comprises a sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 8, or (iii) the VH comprises the amino acid sequence set forth in SEQ ID NO: 7, and the VL comprises the amino acid sequence set forth in SEQ ID NO:

8.

37. 37. The pre-filled syringe of claim 35 or 36, wherein the anti-BDCA2 antibody comprises an immunoglobulin heavy chain and an immunoglobulin light chain, (i) the heavy chain comprises a sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO:9 and the light chain comprises a sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO:10; or (ii) the heavy chain comprises a sequence at least 90% identical to the amino acid sequence of SEQ ID NO:9 and the light chain comprises a sequence at least 90% identical to the amino acid sequence of SEQ ID NO:10; or (iii) The pre-filled syringe, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 9 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:

10.

38. The anti-BDCA2 antibody, the anti-BDCA2 antibody at a concentration of 150 mg / ml; sucrose at a concentration of 3%, L-histidine at a concentration of 20 mM, L-Arginine HCl at a concentration of 100 mM, Glutathione at a concentration of 0.4 mM, and Polysorbate 80 (PS80) at a concentration of 0.05% The pre-filled syringe according to any one of claims 35 to 37, wherein the pharmaceutical composition has a pH of 5.

7.

39. The prefilled syringe according to any one of claims 35 to 38, which is a transparent glass vial of type 1 of the United States Pharmacopoeia or the European Pharmacopoeia, stoppered with a rubber stopper.